litlas
Log inCreate account

Jeffrey A. Bluestone

Active 1985–2025

280
Papers
86,448
Citations
158
h-index
276
i10-index

Citations

Citations per year for Jeffrey A. Bluestone1983: 1 citations1985: 1 citations1986: 3 citations1987: 34 citations1988: 113 citations1989: 150 citations1990: 135 citations1991: 112 citations1992: 121 citations1993: 149 citations1994: 141 citations1995: 255 citations1996: 315 citations1997: 326 citations1998: 454 citations1999: 505 citations2000: 439 citations2001: 440 citations2002: 407 citations2003: 388 citations2004: 459 citations2005: 541 citations2006: 578 citations2007: 601 citations2008: 722 citations2009: 824 citations2010: 776 citations2011: 796 citations2012: 776 citations2013: 795 citations2014: 739 citations2015: 842 citations2016: 726 citations2017: 748 citations2018: 852 citations2019: 2,263 citations2020: 2,574 citations2021: 2,639 citations2022: 2,348 citations2023: 1,840 citations2024: 2,521 citations2025: 1,236 citations2026: 30 citations1984: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 10,265 citing papers, 34.9% of this breakdownChina: 2,971 citing papers, 10.1% of this breakdownUnited Kingdom: 1,913 citing papers, 6.5% of this breakdownGermany: 1,741 citing papers, 5.9% of this breakdownFrance: 1,082 citing papers, 3.7% of this breakdownJapan: 1,081 citing papers, 3.7% of this breakdownItaly: 1,060 citing papers, 3.6% of this breakdownCanada: 994 citing papers, 3.4% of this breakdownAustralia: 740 citing papers, 2.5% of this breakdownNetherlands: 659 citing papers, 2.2% of this breakdownSwitzerland: 612 citing papers, 2.1% of this breakdownSpain: 484 citing papers, 1.6% of this breakdown
0%34.9%Other 19.8%

Institutions

Fields

  • Medicine37.3%
  • Immunology and Microbiology36.2%
  • Biochemistry, Genetics and Molecular Biology22.1%
  • Neuroscience1.8%
  • Engineering0.7%
  • Agricultural and Biological Sciences0.4%
  • Other1.5%

Topics

  • Immune Cell Function and Interaction11.9%
  • T-cell and B-cell Immunology10.9%
  • Immunotherapy and Immune Responses6.6%
  • Cancer Immunotherapy and Biomarkers4%
  • Diabetes and associated disorders3.8%
  • CAR-T cell therapy research3.6%
  • Other59.2%

Coauthors

All papers

Open in search
  1. Multiple early factors anticipate post-acute COVID-19 sequelae

    Authors: Yapeng Su, Dan Yuan, Daniel Chen, Raymond T. Ng, Kai Wang, Jongchan Choi, Sarah Li, Sunga Hong, Rongyu Zhang, Jingyi Xie, Sergey A. Kornilov, Kelsey Scherler, Ana Jimena Pavlovitch-Bedzyk, Shen Dong, Christopher Lausted, Inyoul Lee, Shannon Fallen, Chengzhen L. Dai, Priyanka Baloni, Brett Smith, Venkata R. Duvvuri, Kristin G. Anderson, Jing Li, Fan Yang, Caroline J. Duncombe, Denise J. McCulloch, Clifford Rostomily, Pamela Troisch, Jing Zhou, Sean Mackay, Quinn DeGottardi, Damon May, Ruth Taniguchi, Rachel Gittelman, Mark Klinger, Thomas M. Snyder, Ryan Roper, Gladys Wojciechowska, Kim M. Murray, Rick Edmark, Simon Evans, Lesley Jones, Yong Zhou, Lee Rowen, Rachel Liu, William Chour, Heather A. Algren, William R. Berrington, Julie A. Wallick, Rebecca A. Cochran, Mary Micikas, Terri Wrin, Christos J. Petropoulos, Hunter Cole, Trevan Fischer, Wei Wei, Dave S.�B. Hoon, Nathan D. Price, Naeha Subramanian, Joshua A. Hill, Jennifer Hadlock, Andrew T. Magis, Antoni Ribas, Lewis L. Lanier, Scott D. Boyd, Jeffrey A. Bluestone, Helen Y. Chu, Leroy Hood, Raphaël Gottardo, Philip D. Greenberg, Mark M. Davis, Jason D. Goldman, James R. Heath - Cell 2022 cited by 1,220

  2. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

    Authors: Kevan C. Herold, Brian N. Bundy, S. Alice Long, Jeffrey A. Bluestone, Linda A. DiMeglio, Matthew J. Dufort, Stephen E. Gitelman, Peter A. Gottlieb, Jeffrey P. Krischer, Peter S. Linsley, Jennifer B. Marks, Wayne D. Moore, Antoinette Moran, Henry Rodriguez, William E. Russell, Desmond Schatz, Jay S. Skyler, Eva Tsalikian, Diane K. Wherrett, Anette-Gabriele Ziegler, Carla J. Greenbaum - New England Journal of Medicine 2019 cited by 1,112

  3. Treg cell-based therapies: challenges and perspectives

    Authors: Caroline Raffin, Linda T. Vo, Jeffrey A. Bluestone - Nature reviews. Immunology 2019 cited by 706

  4. CD28 Costimulation: From Mechanism to Therapy

    Authors: Jonathan H. Esensten, Ynes Helou, Gaurav Chopra, Arthur Weiss, Jeffrey A. Bluestone - Immunity 2016 cited by 947

  5. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis

    Authors: Noriko Komatsu, Kazuo Okamoto, Shinichiro Sawa, Tomoki Nakashima, Masatsugu Oh‐hora, Tatsuhiko Kodama, Sakae Tanaka, Jeffrey A. Bluestone, Hiroshi Takayanagi - Nature Medicine 2013 cited by 1,128

  6. Type 1 diabetes immunotherapy using polyclonal regulatory T cells

    Authors: Jeffrey A. Bluestone, Jane H. Buckner, Mark Fitch, Stephen E. Gitelman, Shipra Gupta, Marc K. Hellerstein, Kevan C. Herold, Angela Lares, Michael R. F. Lee, Kelvin Li, Weihong Liu, S. Alice Long, Lisa M. Masiello, Vinh Nguyen, Amy Putnam, Mary Rieck, Peter H. Sayre, Qizhi Tang - Science Translational Medicine 2015 cited by 1,013

  7. Revisiting IL-2: Biology and therapeutic prospects

    Authors: Abul K. Abbas, Eleonora Trotta, Dimitre R. Simeonov, Alexander Marson, Jeffrey A. Bluestone - Science Immunology 2018 cited by 633

  8. Next-generation regulatory T cell therapy

    Authors: Leonardo M. R. Ferreira, Yannick D. Müller, Jeffrey A. Bluestone, Qizhi Tang - Nature Reviews Drug Discovery 2019 cited by 473

  9. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis

    Authors: James Lee, Sadaf Mehdizadeh, Jennifer Smith, Arabella Young, Ilgiz A. Mufazalov, Cody T. Mowery, Adil Daud, Jeffrey A. Bluestone - Science Immunology 2020 cited by 300

  10. CTLA-4 can function as a negative regulator of T cell activation

    Authors: Theresa L. Walunas, Deborah J. Lenschow, Christina Y. Bakker, Peter S. Linsley, Gordon J. Freeman, Jonathan M. Green, Craig B. Thompson, Jeffrey A. Bluestone - Immunity 1994 cited by 2,198

  11. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes

    Authors: Jonathan T. Sockolosky, Eleonora Trotta, Giulia Parisi, Lora K. Picton, Leon Su, Alan Le, Akanksha Chhabra, Stephanie Silveria, Benson M. George, Indigo C. King, Matthew Tiffany, Kevin M. Jude, Leah V. Sibener, David Baker, Judith A. Shizuru, Antoni Ribas, Jeffrey A. Bluestone, K. Christopher García - Science 2018 cited by 373

  12. Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways

    Authors: Brian T. Fife, Jeffrey A. Bluestone - Immunological Reviews 2008 cited by 1,034

  13. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo

    Authors: Xuyu Zhou, Samantha L. Bailey-Bucktrout, Lukas T. Jeker, Cristina Peñaranda, Marc Martínez‐Llordella, Meredith Ashby, Maki Nakayama, Wendy Rosenthal, Jeffrey A. Bluestone - Nature Immunology 2009 cited by 1,339

  14. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

    Authors: Weihong Liu, Amy Putnam, Zhou Xu-yu, Gregory L. Szot, Michael R. Lee, Shirley Zhu, Peter A. Gottlieb, Philipp Kapranov, T Gingeras, Barbara Fazekas de St Groth, Carol Clayberger, David M. Soper, Steven F. Ziegler, Jeffrey A. Bluestone - The Journal of Experimental Medicine 2006 cited by 2,584

  15. Innate immunity and intestinal microbiota in the development of Type 1 diabetes

    Authors: Wen Li, Ruth E. Ley, Pavel Volchkov, P. Benjamin Stranges, Lia Avanesyan, Austin C. Stonebraker, Changyun Hu, F. Susan Wong, Gregory L. Szot, Jeffrey A. Bluestone, Jeffrey I. Gordon, Alexander V. Chervonsky - Nature 2008 cited by 1,930

  16. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials

    Authors: Birgit Sawitzki, Paul Harden, Petra Reinke, Aurélie Moreau, James A. Hutchinson, David Game, Qizhi Tang, Eva C. Guinan, Manuela Battaglia, William J. Burlingham, Ian S.D. Roberts, Mathias Streitz, Régis Josien, Carsten A. Böger, Cristiano Scottà, James F. Markmann, Joanna Hester, Karsten Juerchott, Cécile Braudeau, Ben James, Laura Contreras‐Ruiz, Jeroen B. van der Net, Tobias Bergler, Rossana Caldara, William Petchey, Matthias Edinger, Nathalie Dupas, Michael Kapinsky, Ingrid Mutzbauer, Natalie Otto, Robert Öllinger, María P. Hernández-Fuentes, Fadi Issa, Norbert Ahrens, Christoph Meyenberg, Sandra Karitzky, Ulrich Kunzendorf, Stuart J. Knechtle, Josep M. Grinyó, Peter J. Morris, L Brent, Andrew Bushell, Laurence A. Turka, Jeffrey A. Bluestone, Robert I. Lechler, Hans J. Schlitt, María Cristina Cuturi, Stephan Schlickeiser, Peter J. Friend, Tewfik Miloud, Alexander Scheffold, Antonio Secchi, Kerry Crisalli, Sang‐Mo Kang, Rachel Hilton, Bernhard Banas, Gilles Blancho, Hans‐Dieter Volk, Giovanna Lombardi, Kathryn J. Wood, Edward K. Geissler - The Lancet 2020 cited by 451

  17. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency

    Authors: David N. Nguyen, Theodore L. Roth, P. Jonathan Li, Peixin Amy Chen, Ryan Apathy, Murad R. Mamedov, Linda T. Vo, Victoria Tobin, Daniel B. Goodman, Eric Shifrut, Jeffrey A. Bluestone, Jennifer M. Puck, Francis C. Szoka, Alexander Marson - Nature Biotechnology 2019 cited by 325

  18. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

    Authors: Yapeng Su, Daniel Chen, Dan Yuan, Christopher Lausted, Jongchan Choi, Chengzhen L. Dai, Valentin Voillet, Venkata R. Duvvuri, Kelsey Scherler, Pamela Troisch, Priyanka Baloni, Guangrong Qin, Brett Smith, Sergey A. Kornilov, Clifford Rostomily, Alexander M. Xu, Jing Li, Shen Dong, Alissa C. Rothchild, Jing Zhou, Kim M. Murray, Rick Edmark, Sunga Hong, John E. Heath, John C. Earls, Rongyu Zhang, Jingyi Xie, Sarah Li, Ryan Roper, Lesley Jones, Yong Zhou, Lee Rowen, Rachel Liu, Sean Mackay, D. Shane O’Mahony, Christopher Dale, Julie A. Wallick, Heather A. Algren, Michael Zager, Wei Wei, Nathan D. Price, Sui Huang, Naeha Subramanian, Kai Wang, Andrew T. Magis, Jennifer Hadlock, Leroy Hood, Alan Aderem, Jeffrey A. Bluestone, Lewis L. Lanier, Philip D. Greenberg, Raphaël Gottardo, Mark M. Davis, Jason D. Goldman, James R. Heath - Cell 2020 cited by 644

  19. CRISPR screen in regulatory T cells reveals modulators of Foxp3

    Authors: Jessica T. Cortez, Elena Montauti, Eric Shifrut, Jovylyn Gatchalian, Yusi Zhang, Oren Shaked, Yuanming Xu, Theodore L. Roth, Dimitre R. Simeonov, Yana Zhang, Siqi Chen, Zhongmei Li, Jonathan M. Woo, Josephine Ho, Ian Vogel, Grace Y. Prator, Bin Zhang, Youjin Lee, Zhaolin Sun, Igal Ifergan, Frédéric Van Gool, Diana C. Hargreaves, Jeffrey A. Bluestone, Alexander Marson, Deyu Fang - Nature 2020 cited by 236

  20. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes

    Authors: Shen Dong, Kamir J. Hiam-Galvez, Cody T. Mowery, Kevan C. Herold, Stephen E. Gitelman, Jonathan H. Esensten, Weihong Liu, Angela Lares, Ashley Leinbach, Michael Lee, Vinh Nguyen, Stanley Tamaki, Whitney Tamaki, Courtney Tamaki, Morvarid Mehdizadeh, Amy Putnam, Matthew H. Spitzer, Chun Ye, Qizhi Tang, Jeffrey A. Bluestone - JCI Insight 2021 cited by 221

  21. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins

    Authors: Kathrin Schumann, Steven Lin, Eric Boyer, Dimitre R. Simeonov, Meena Subramaniam, Rachel E. Gate, Genevieve Haliburton, Chun Ye, Jeffrey A. Bluestone, Jennifer A. Doudna, Alexander Marson - National Academy of Sciences, Proceedings of the National Academy of Sciences 2015 cited by 723

  22. Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity

    Authors: David Wang, Jason Quiros, Kelly M. Mahuron, Chien-Chun Steven Pai, Valeria Ranzani, Arabella Young, Stephanie Silveria, Tory Harwin, Arbi Abnousian, Massimiliano Pagani, Michael D. Rosenblum, Frédéric Van Gool, Lawrence Fong, Jeffrey A. Bluestone, Michel DuPage - Cell Reports 2018 cited by 310

  23. Opportunities for Treg cell therapy for the treatment of human disease

    Authors: Jeffrey A. Bluestone, Brent S. McKenzie, Joshua Beilke, Fred Ramsdell - Frontiers in Immunology 2023 cited by 124

  24. In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes

    Authors: Qizhi Tang, Kammi Henriksen, Mingying Bi, Erik B. Finger, Gregory L. Szot, Jianqin Ye, Emma L. Masteller, Hugh O. McDevitt, Mark Bonyhadi, Jeffrey A. Bluestone - The Journal of Experimental Medicine 2004 cited by 1,214